Avanir Deal Partly Plugs Otsuka’s Abilify Gap
This article was originally published in PharmAsia News
Executive Summary
While some eyebrows are being raised over the sum Otsuka Pharmaceutical is proposing to shell out for a small U.S. CNS company with only one niche marketed product, the pipeline the deal will bring is being viewed positively by some analysts.
You may also be interested in...
Otsuka Bags Novel Antibody Tech, Pipeline In $430m Visterra Buy
Otsuka liked the private US antibody tech company Visterra so much that it is buying it, in a move developing out of licensing discussions and which the Japanese firm says will strengthen its presence in biologics for renal disorders and other high-need areas.
What COVID Spotlight Means For Pharma – In Their Own Words
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Deal Watch: Bristol Teams Up With Insitro, Sensyne In AI-Directed Collaborations
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Need a specific report? 1000+ reports available
Buy Reports